8/103 sources · 3 publishersUpdated Nov 5, 17:25 UTC
Amylyx reports no product revenue as avexitide FDA filing remains on track
Amylyx Pharmaceuticals reported no product revenue and a Q3 net loss of $45.49M, up 32.3% YoY. Operating expenses rose 38% to $49.7 million, while research and development spending increased to $28.4 million. The company said it remains on track to submit an avexitide NDA to the FDA by year-end 2026, after the Phase 3 trial met its primary endpoint.
Why it matters
The results show Amylyx remains pre-commercial, with higher spending ahead of a potential avexitide launch. The company’s planned FDA submission keeps the regulatory milestone in focus, while the eventual approval label and indication remain unresolved.
Key facts
- 1Amylyx reported no product revenue and a net loss of $45.49M, up 32.3% YoY, in Q3 2026. tradingview.com
- 2Third-quarter operating expenses increased 38% to $49.7 million, including research and development expenses of $28.4 million. finance.yahoo.com
- 3Amylyx plans to submit an NDA for avexitide to the FDA by year-end 2026. tradingview.com
- 4The company estimates that approximately 160,000 people in the U.S. have post-bariatric hypoglycemia. finance.yahoo.com
Open questions
- Amylyx said the eventual scope, label and indication of any avexitide approval cannot yet be determined.
- The company did not provide enrollment figures for its expanded access program or a forecast for launch patients.
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.